sta363
Discogenic Pain
Stayble TherapeuticsPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Discogenic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PAMIDRONIC ACID University Hospital, Clermont-Ferrand | Phase 2 | CCC |
Cordstem-Dd CHABiotech CO., Ltd | Phase 1/2 | CCC |
Fibrin Sealant Pauza, Kevin, MD | Phase 2/3 | NR |
Fibrin Sealant Pauza, Kevin, MD | Phase 2/3 | NR |
Ren-1654 Renovis | Phase 2 | NR |
Same molecule, other indications
sta363 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →